Meeting
2023 ASCO Genitourinary Cancers Symposium
Phase 2 randomized total eradication of metastatic lesions following definitive radiation to the prostate in de novo oligometastatic prostate cancer (TERPs) trial.
Authors
Zaker Hamid Rana
University of Maryland School of Medicine, Baltimore, MD
Zaker Hamid Rana , Nicole Helie , Caitlin Eggleston , Kaysee Baker , Jason K. Molitoris , Matthew J. Ferris , Akshar Patel , Young Kwok , Sarah McAvoy , Dan Kunaprayoon , Jack J. Hong , Matthew Deek , Philip Sutera , Rebecca A Deek , Soren Bentzen , Minhaj Siddiqui , Heather Dorothy Mannuel , Arif Hussain , Phuoc T. Tran , Mark V. Mishra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Clinical Trial Registration Number
NCT05223803
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS275)
DOI
10.1200/JCO.2023.41.6_suppl.TPS275
Abstract #
TPS275
Poster Bd #
P17
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II randomized trial of RAdium-223 dichloride and SABR versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
First Author: Matthew Pierre Deek
Poster
2024 ASCO Genitourinary Cancers Symposium
ARTO trial: Overall survival analysis from a randomized phase II trial testing the benefit of adding stereotactic body radiotherapy to abiraterone acetate in patients with oligometastatic castrate-resistant prostate cancer.
First Author: Giulio Francolini
Poster
2024 ASCO Genitourinary Cancers Symposium
Mature results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone.
First Author: Jonathan David Tward
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz